Novo Nordisk raises 2017 forecasts despite continued US price pressure
Copenhagen
NOVO Nordisk, the world's leading maker of diabetes drugs, reported a better than expected profit on Wednesday driven by new diabetes and obesity drugs, though it said sale prices would remain under pressure in the United States.
The Danish drugmaker shocked markets in 2016 by cutting its long-term operating profit forecasts twice on the back of price pressures in its main US market, sending its shares down more than 40 per cent last year.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Nestle sales growth sputters on US slump, vitamin snags
BNP Paribas beats estimates as lower costs offset trading slump
TikTok ultimatum puts US firms in firing line for China response
Toyota and Nissan pair up with Tencent and Baidu for China AI arms race
BHP targets Anglo American in bid valuing miner at US$39 billion
FTSE 100 hits record high on big mining M&A, earnings push